MARKET

CASI

CASI

CASI Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.520
-0.020
-0.79%
Opening 09:52 03/02 EST
OPEN
2.640
PREV CLOSE
2.540
HIGH
2.657
LOW
2.515
VOLUME
64.64K
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
1.150
MARKET CAP
312.34M
P/E (TTM)
-5.6125
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Angiogenesis Modulators Professional Survey Market Outlook, Industry Analysis and Prospect 2021-2026
Mar 01, 2021 (Heraldkeepers) -- Angiogenesis is the physiological process of forming new blood vessels from existing blood vessels, which are formed in the...
Heraldkeepers · 1d ago
We're Hopeful That CASI Pharmaceuticals (NASDAQ:CASI) Will Use Its Cash Wisely
Simply Wall St. · 5d ago
Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size,Market Share, Application Analysis,Regional outlook,Growth,Trends,Key Players,Competitive Strategies and Forecast 2020 to 2027 By Ameco Research
Comserve · 02/22 05:54
Aurora Kinase A Market Sales and Revenue Analysis Report 2020 to 2027 By Ameco Research
Comserve · 02/22 04:42
Aurora Kinase A Industry 2021 Manufacturers Strategy with Growth Rate, Growing Share, Market Size, Revenue and Forecast to 2027 | Industry Research Biz
Feb 19, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Aurora Kinase A Market”...
The Express Wire · 02/19 05:24
Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Growth 2021 By Sales, Trends, Supply, Emerging Demand, Organization Size, Innovative Technology, Growing Prominence Analysis & Forecast to 2027
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Hypoxia Inducible Factor 1...
The Express Wire · 02/18 05:28
H.C. Wainwright Keeps Their Buy Rating on CASI Pharmaceuticals (CASI)
H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on CASI Pharmaceuticals (CASI) today and set a price target of $3.50. The company's shares
SmarterAnalyst · 02/17 11:29
8-K: CASI Pharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- 0000895051 false 0000895051 2021-02-16 2021-02-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/16 22:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CASI. Analyze the recent business situations of CASI Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CASI stock price target is 4.000 with a high estimate of 5.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 42.23M
% Owned: 34.07%
Shares Outstanding: 123.94M
TypeInstitutionsShares
Increased
30
3.54M
New
18
55.37K
Decreased
17
1.77M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.99%
Pharmaceuticals & Medical Research
-0.06%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Wei-Wu He
President
Wei Zhang
Chief Financial Officer/Chief Accounting Officer
Weihao Xu
Other
Alexander Zukiwski
Independent Director
James Huang
Independent Director
Franklin Salisbury
Independent Director
Rajesh Shrotriya
Independent Director
Y. Alexander Wu
Independent Director
Quan Zhou
  • Dividends
  • Splits
  • Insider Activity
No Data
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.